TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
about
NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell EngraftmentB cells in chronic graft-versus-host diseaseThe immunoregulatory role of type I and type II NKT cells in cancer and other diseasesHigh-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.Splenocyte Infusion and Whole-Body Irradiation for Induction of Peripheral Tolerance in Porcine Lung Transplantation: Modifications of the Preconditioning Regime for Improved Clinical FeasibilityMeasurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencingPath to clinical transplantation tolerance and prevention of graft-versus-host disease.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen.The biology of graft-versus-host disease: experimental systems instructing clinical practice.Advances in graft-versus-host disease biology and therapy.Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia.α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic TransplantationCD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHDBiomarkers in chronic graft-versus-host diseaseNon-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanismTolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplantsProphylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidenceRapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignanciesAllogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.Prevention of graft-vs.-host diseaseRegulatory T Cell Immunotherapy in Immune-Mediated DiseasesFavorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia.Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.Cellular therapy following allogeneic stem-cell transplantation.H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplantsPhase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategyIncidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte GlobulinMinimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation.Stable mixed chimerism and tolerance to human organ transplants.Acute graft-versus-host disease: from the bench to the bedside.
P2860
Q26765845-D91920DF-62CA-4158-A6E2-FEA3AFB529C8Q26861706-45936C30-E30B-48EC-A7AE-E69FB1189D8AQ27027556-472CBCC8-F681-4213-B11C-43D60C3672A6Q31043227-5D8A83D6-3C24-4F21-98A8-0D1D515F63F5Q33443622-DB7CA58A-2AE9-465E-BCC6-8EBA6FCAF584Q33531727-B00867CF-C4C2-4DB0-BDFA-49712B0BAC22Q33734003-072967C8-5A3E-43AB-9D95-6CDD7AEFEE45Q33771667-117BD57F-2FF5-4A2C-B732-D131C85AB476Q33901277-AC0428BC-2886-4DE2-ACD3-73D9C7DDD9C4Q33917175-9D197823-2655-4F16-8EBD-E9551CDD7AB7Q34031916-21653B93-7B47-480F-9C35-83B4E249371EQ34109670-108E6C69-3B57-494B-B807-590E50F3E306Q34431458-3BCE7271-5034-41C2-9873-50D0F3C78B68Q34462528-DF90C4DB-EFA6-40FC-8C0B-5B22FFF31623Q34707286-4CA22FD2-F1D2-46A2-8E66-E4823C97D503Q35094374-B2A27DFC-373E-4F7E-A88E-3F3592BA85A7Q35095722-4C270DB7-65CA-4A07-AD6B-4662F0B79AF0Q35127172-DFBDFB51-C037-42BC-976A-DE54079F26EEQ35317371-FCDF75BA-F846-4FBA-8FD1-3783AF7AB788Q35607308-E7A2EC51-2D6B-40BD-9977-CAF0B9BD0061Q35662003-712FE16F-2602-41C4-A115-A12C064E5E74Q35866143-BC2EEC91-40D6-44A1-A11C-AE4EF6942B02Q35918706-22B6DC90-33F7-4E55-9280-1FAC63761EFAQ36057911-F34AB731-EC86-4B41-8C2A-A4168D174E90Q36256781-8B52F5A3-A578-4B16-8E86-52996A6B70E8Q36426327-4E5324AA-E9D7-491B-9EE1-38C56A51BBE5Q36431047-3AF1D044-448A-4969-B6CA-01676BBC1F79Q36462109-A2036A18-19B1-489E-8E5E-0A7CD43D5903Q36514033-C32EE2BF-C88D-47BE-9CDD-B952B08FF99BQ36570651-E33B5557-044A-4401-B6A5-FD39087BCF6BQ36612643-8862FD88-7354-4B6F-8334-E0908A77D583Q36637621-E1819807-19EE-4B4E-87D8-E2327FAC07E5Q36727857-9E5D346E-1E83-401E-8B6F-B396D740C382Q36761521-AB0BF468-44D5-41C0-B613-172AB7E2DCF8Q36779768-983D0508-B901-4E3C-BDC9-7DEBC392016BQ36838087-2E9C9CB2-E0DC-4F18-9C4B-7EDB2D500059Q37087424-3DC6C368-5DF9-46C2-826A-C42FA22E999EQ37272005-3D980FBB-AAC5-465D-89F0-59CBB8C6DC66Q37337098-80B0F33F-FB5F-4758-9577-C437A0C33914Q37420496-A4BF1FAB-8047-4F64-A37D-055353B64438
P2860
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TLI and ATG conditioning with ...... related and unrelated donors.
@en
TLI and ATG conditioning with ...... related and unrelated donors.
@nl
type
label
TLI and ATG conditioning with ...... related and unrelated donors.
@en
TLI and ATG conditioning with ...... related and unrelated donors.
@nl
prefLabel
TLI and ATG conditioning with ...... related and unrelated donors.
@en
TLI and ATG conditioning with ...... related and unrelated donors.
@nl
P2093
P2860
P1433
P1476
TLI and ATG conditioning with ...... related and unrelated donors.
@en
P2093
Brit B Turnbull
David B Miklos
Ginna G Laport
Holbrook E Kohrt
Judith A Shizuru
Karl G Blume
Kartoosh Heydari
Laura J Johnston
Philip W Lavori
Richard T Hoppe
P2860
P304
P356
10.1182/BLOOD-2009-03-211441
P407
P577
2009-05-07T00:00:00Z